drugset
drugset / Trial / NCT04445389

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

NCT04445389 ↗

Phase 1/2 Terminated 60 enrolled Genexine, Inc.
RandomizedSequentialDouble-blindPrevention

Summary

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.

Timeline

Start
2020-06-17
Primary completion
2020-12-17
Completion
2020-12-17

Outcome

Outcome not reported

Stopped (Business): “The sponsor decided to change the investigational product for a strategic reason.”

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-19 Vaccine — Intramuscular

Indications

COVID-19